Table 6. Associations between changes in NT-proBNP and changes in selected markers of arthritis activity after 6 months of treatment.

	Crude			Multiple median regression
	Spearman´s rho	95% CI	P-value	Beta	95% CI	P-value
ΔCRP
All	0.30	0.12–0.46	0.002	0.78	0.43–1.14	< 0.001
RA	0.35	0.11–0.55	0.005	1.26	0.69–1.83	< 0.001
PsA	0.29	-0.09–0.59	0.13	1.56	0.76–2.36	< 0.001
AS	-0.03	-0.47–0.42	0.90	0.31	-0.16–0.77	0.19
MTX	0.32	0.04–0.55	0.026	1.56	0.91–2.21	< 0.001
TNFi±MTX	0.29	0.05–0.50	0.02	0.14	-0.32–0.60	0.54
ΔESR
All	0.26	0.08–0.43	0.006	0.77	0.26–1.28	0.004
RA	0.29	0.05–0.51	0.019	0.74	0.16–1.31	0.013
PsA	0.27	-0.11–0.58	0.16	0.59	-1.35–2.54	0.54
AS	0.15	-0.32–0.55	0.53	0.7	-1.33–1.53	0.094
MTX	0.25	-0.04–0.49	0.09	1.09	0.16–2.02	0.023
TNFi±MTX	0.26	0.02–0.48	0.037	0.31	-0.44–1.06	0.41
ΔDAS28 (in RA)
RA	0.52	0.24–0.72	0.0007	14.7	-0.54–29.9	0.058
MTX	0.73	0.42–0.89	0.0004	22	-203–247	0.84
TNFi±MTX	0.46	0.02–0.75	0.043	17.9	1.58–34.3	0.034
MHAQ
All	0.19	0.01–0.36	0.039	16.4	-7.3–40.1	0.17
RA	0.18	-0.07–0.41	0.15	23.8	-14.7–62.4	0.22
PsA	0.17	-0.21–0.50	0.37	25.4	-29.9–80.8	0.35
AS	0.18	-0.29–0.57	0.45	-3.8	-62.9–55.3	0.89
MTX	0.06	-0.22–0.33	0.69	13.3	-41.9–68.5	0.63
TNFi±MTX	0.29	0.04–0.50	0.022	39.1	7.4–70.8	0.017

Bold values denote statistical significance at the p < 0.05 level.

Δ indicates change from baseline to 6 months.

Abbreviations: RA: Rheumatoid arthritis, PsA: Psoriatic arthritis, AS: Ankylosing spondylitis, MTX: Methotrexate, TNFi: Tumor necrosis factor inhibitors, NT-proBNP: N-terminal pro-brain natriuretic peptide, rho: Spearman’s rho, CRP: C-reactive protein, ESR: Erythrocyte sedimentation rate, DAS28: Disease Activity Score for 28 joints, MHAQ: Modified Health Assessment Questionnaire.